ACHE and Alzheimer disease: Limited treatments are available to delay AD development, such as small molecules (e.g., glutamate modulators, acetylcholinesterase inhibitors) to improve synaptic function and immunotherapy (e.g., anti-Aβ: lecanemab, donanemab, or anti-β/γ-secretases) to remove plaques and reduce tau tangles, but have had modest success (7, 8, 86, 87).